## Chi-An Chen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/799618/publications.pdf

Version: 2024-02-01

134610 156644 4,348 142 34 58 citations h-index g-index papers 143 143 143 6636 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	<scp>PET</scp> / <scp>MRI</scp> in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival. Journal of Magnetic Resonance Imaging, 2021, 53, 305-318.	1.9	9
2	Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer. Cancers, 2021, 13, 1386.	1.7	1
3	Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A populationâ€based analysis. Cancer Medicine, 2021, 10, 6845-6854.	1.3	3
4	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	1.4	4
5	CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. Endocrine-Related Cancer, 2019, 26, 73-88.	1.6	14
6	Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center. International Journal of Environmental Research and Public Health, 2019, 16, 2561.	1,2	9
7	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Frontiers in Pharmacology, 2019, 10, 426.	1.6	21
8	Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers, 2019, 11, 1400.	1.7	45
9	mTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines through Modulating Dendritic Cell Function in the Tumor Microenvironment. Cancers, 2019, 11, 617.	1.7	11
10	Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers, 2019, 11, 270.	1.7	19
11	Clear Cell Carcinoma of the Abdominal Wall as a Rare Complication of General Obstetric and Gynecologic Surgeries: 15 Years of Experience at a Large Academic Institution. International Journal of Environmental Research and Public Health, 2019, 16, 552.	1.2	14
12	Primary Ewing Family of Tumor Arising in the Ovary: A Case Report. International Journal of Gynecological Pathology, 2019, 38, 470-473.	0.9	3
13	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes. , 2019, 7, 313.		67
14	Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Cancer Letters, 2019, 444, 20-34.	3.2	13
15	Large cell neuroendocrine carcinoma of the endometrium: A case report and literature review. Taiwanese Journal of Obstetrics and Gynecology, 2018, 57, 144-149.	0.5	18
16	Torsion of pedunculated subserous uterine leiomyoma: A rare complication of a common disease. Taiwanese Journal of Obstetrics and Gynecology, 2018, 57, 300-303.	0.5	18
17	Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Letters, 2018, 425, 152-163.	3.2	31
18	Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment. Molecular Therapy, 2018, 26, 404-419.	3.7	33

#	Article	IF	CITATIONS
19	Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study. Journal of Gynecologic Oncology, 2018, 29, e55.	1.0	3
20	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. Epigenomics, 2018, 10, 1397-1413.	1.0	14
21	Factors predicting parametrial invasion in patients with early-stage cervical carcinomas. PLoS ONE, 2018, 13, e0204950.	1.1	12
22	Long-term outcomes of surgical treatment for intravascular leiomyomatosis. Journal of the Formosan Medical Association, 2018, 117, 964-972.	0.8	8
23	Radical trachelectomy for early stage cervical cancer: A case series and literature review. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 143-146.	0.5	9
24	Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 442-448.	0.5	13
25	Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Frontiers in Pharmacology, 2017, 8, 800.	1.6	12
26	Clinical management and risk reduction in women with low-grade squamous intraepithelial lesion cytology: A population-based cohort study. PLoS ONE, 2017, 12, e0188203.	1.1	8
27	Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine. American Journal of Cancer Research, 2016, 6, 157-72.	1.4	5
28	Urokinase-type Plasminogen Activator Resulting from Endometrial Carcinogenesis Enhances Tumor Invasion and Correlates with Poor Outcome of Endometrial Carcinoma Patients. Scientific Reports, 2015, 5, 10680.	1.6	13
29	Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated wholeâ€body PET/MR: Correlation with pathological prognostic factors. Journal of Magnetic Resonance Imaging, 2015, 42, 1723-1732.	1.9	45
30	Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Journal of Gynecologic Oncology, 2015, 26, 46.	1.0	38
31	IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients. Endocrine-Related Cancer, 2015, 22, 703-711.	1.6	11
32	Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation. Cancer Letters, 2015, 359, 117-126.	3.2	39
33	Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Modern Pathology, 2015, 28, 303-311.	2.9	31
34	The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. Annals of Surgical Oncology, 2015, 22, 1556-1565.	0.7	31
35	Establishment of a New Ovarian Cancer Cell Line CA5171. Reproductive Sciences, 2015, 22, 725-734.	1.1	5
36	Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget, 2015, 6, 39740-39755.	0.8	33

#	Article	IF	Citations
37	Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. American Journal of Translational Research (discontinued), 2015, 7, 139-52.	0.0	5
38	A Prospective Study of Gynecological Cancer Risk in Relation to Adiposity Factors: Cumulative Incidence and Association with Plasma Adipokine Levels. PLoS ONE, 2014, 9, e104630.	1.1	18
39	Arsenic Trioxide Inhibits CXCR4-Mediated Metastasis by Interfering miR-520h/PP2A/NF-κB Signaling in Cervical Cancer. Annals of Surgical Oncology, 2014, 21, 687-695.	0.7	23
40	Screening Frequency and Atypical Cells and the Prediction of Cervical Cancer Risk. Obstetrics and Gynecology, 2014, 123, 1003-1011.	1.2	6
41	Superficial angiomyxoma on the vulva of an adolescent. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 104-106.	0.5	7
42	The correlations of sexual activity, sleep problems, emotional distress, attachment styles with quality of life: comparison between gynaecological cancer survivors and noncancer women. Journal of Clinical Nursing, 2014, 23, 985-994.	1.4	11
43	Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study. European Journal of Cancer, 2014, 50, 3161-3167.	1.3	8
44	Solitary primary peritoneal carcinoma arising from the omentum. Taiwanese Journal of Obstetrics and Gynecology, 2014, 53, 256-259.	0.5	3
45	Validating a rapid, real-time, PCR-based direct mutation detection assay for preimplantation genetic diagnosis. Gene, 2014, 548, 299-305.	1.0	14
46	Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecologic Oncology, 2013, 131, 63-68.	0.6	20
47	High-risk human papillomavirus, other than type 16/18, in predominantly older Taiwanese women with high-grade cervical preinvasive lesions. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 222-226.	0.5	10
48	The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecologic Oncology, 2013, 128, 239-244.	0.6	68
49	Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. Endocrine-Related Cancer, 2013, 20, 213-227.	1.6	19
50	Clinical features and outcomes of neck lymphatic metastasis in ovarian epithelial carcinoma. World Journal of Surgical Oncology, 2013, 11, 255.	0.8	9
51	Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. Journal of Gynecologic Oncology, 2013, 24, 342.	1.0	99
52	Fusion Protein Vaccines Targeting Two Tumor Antigens Generate Synergistic Anti-Tumor Effects. PLoS ONE, 2013, 8, e71216.	1.1	4
53	Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochemical Journal, 2012, 442, 293-302.	1.7	129
54	Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects. Clinical Science, 2012, 123, 347-360.	1.8	12

#	Article	IF	Citations
55	Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1158-1166.	1.3	14
56	Subcutaneous mass as the primary manifestation of gestational choriocarcinoma: A case report. Gynecologic Oncology Case Reports, 2012, 2, 11-13.	0.9	0
57	Malignant struma ovarii complicated by Trousseau's syndrome and repeated episodes of cerebral ischemic strokes: A case report. Gynecologic Oncology Case Reports, 2012, 2, 35-38.	0.9	6
58	New primers for methylation-specific polymerase chain reaction enhance specificity of detecting STAT1 methylation. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 43-49.	0.5	5
59	Serous ovarian carcinoma patients with high alphaâ€folate receptor had reducing survival and cytotoxic chemoâ€response. Molecular Oncology, 2012, 6, 360-369.	2.1	113
60	Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. PLoS ONE, 2012, 7, e47190.	1.1	25
61	Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in Taiwan. PLoS ONE, 2012, 7, e51372.	1.1	43
62	Impact of various treatment modalities on the outcome of stage IB1 $\hat{a}$ $\in$ "IIA cervical adenocarcinoma. International Journal of Gynecology and Obstetrics, 2011, 112, 135-139.	1.0	8
63	Brain metastasis as a late manifestation of ovarian carcinoma. European Journal of Cancer Care, 2011, 20, 44-49.	0.7	26
64	Post-coital vaginal douching is risky for non-regression of low-grade squamous intraepithelial lesion of the cervix. Gynecologic Oncology, 2011, 120, 449-453.	0.6	14
65	IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer. Cancer Research, 2011, 71, 424-434.	0.4	184
66	Histone Deacetylase 6 Regulates Estrogen Receptor $\hat{l}_{\pm}$ in Uterine Leiomyoma. Reproductive Sciences, 2011, 18, 755-762.	1.1	26
67	Quality of life of patients with ovarian cancer in Taiwan: validation and application of the Taiwan Chinese version of the EORTC QLQâ€OV28. Psycho-Oncology, 2010, 19, 782-785.	1.0	10
68	Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. Archives of Gynecology and Obstetrics, 2010, 281, 683-695.	0.8	9
69	The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. Journal of Psychosomatic Obstetrics and Gynaecology, 2010, 31, 16-23.	1.1	43
70	Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis. Molecular Therapy, 2010, 18, 1233-1243.	3.7	85
71	Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox $\hat{A}^{\circ}$ ) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecologic Oncology, 2009, 112, 35-39.	0.6	18
72	Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology, 2009, 256, 83-91.	2.0	74

#	Article	IF	Citations
73	Concurrent Endometrial Carcinoma in Patients with a Curettage Diagnosis of Endometrial Hyperplasia. Journal of the Formosan Medical Association, 2009, 108, 502-507.	0.8	21
74	Clinical Significance of Cytologic Atypical Squamous Cells of Undetermined Significance. Obstetrics and Gynecology, 2009, 113, 888-894.	1.2	8
75	Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochemical Journal, 2009, 424, 449-458.	1.7	61
76	Comparison of the mismatch-specific endonuclease method and denaturing high-performance liquid chromatography for the identification of HBB gene mutations. BMC Biotechnology, 2008, 8, 62.	1.7	11
77	Identification of deletion and duplication genotypes of the <b><i>PMP22</i></b> gene using PCRâ€RFLP, competitive multiplex PCR, and multiplex ligationâ€dependent probe amplification: A comparison. Electrophoresis, 2008, 29, 618-625.	1.3	13
78	Ruptured Pseudoaneurysm of the External Iliac Artery in an Advanced Cervical Cancer Patient Treated by Endovascular Covered Stent Placement. Journal of the Formosan Medical Association, 2008, 107, 348-351.	0.8	12
79	IL-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy Through Antigen Processing and Anti-apoptotic Pathways. Molecular Therapy, 2007, 15, 1890-1897.	3.7	23
80	Cervical Abscess with Vaginal Fistula After Extraperitoneal Cesarean Section. Journal of the Formosan Medical Association, 2007, 106, 1048-1051.	0.8	4
81	Clear Cell Adenocarcinoma of the Uterine Cervix. Taiwanese Journal of Obstetrics and Gynecology, 2007, 46, 453-455.	0.5	5
82	Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer, 2007, 110, 420-431.	2.0	20
83	DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecologic Oncology, 2007, 107, 404-412.	0.6	30
84	Septic Shock after Intracervical Laminaria Insertion. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 76-78.	0.5	2
85	Submucous Myoma Induces Uterine Inversion. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 159-161.	0.5	15
86	Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Modern Pathology, 2006, 19, 1570-1577.	2.9	17
87	A rapid and reliable detection system for the analysis of PMP22 gene dosage by MP/DHPLC assay. Journal of Human Genetics, 2006, 51, 227-235.	1.1	8
88	Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecologic Oncology, 2006, 101, 423-428.	0.6	79
89	Leiomyomatosis with Extension to the Left Gluteal Muscle, Inferior Vena Cava, and Right Atrium. American Journal of Roentgenology, 2006, 187, W546-W547.	1.0	2
90	Chimeric DNA Vaccine Reverses Morphine-Induced Immunosuppression and Tumorigenesis. Molecular Therapy, 2006, 13, 203-210.	3.7	22

#	Article	IF	CITATIONS
91	Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Research, 2006, 26, 4721-8.	0.5	41
92	Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology, 2005, 115, 136-149.	2.0	13
93	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor ÎB. Oncogene, 2005, 24, 390-398.	2.6	61
94	Epidemiologic correlates of cervical human papillomavirus prevalence in women with abnormal Pap smear tests: A Taiwan cooperative oncology group (TCOG) study. Journal of Medical Virology, 2005, 77, 273-281.	2.5	26
95	A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor Growth. Cancer Research, 2005, 65, 4827-4835.	0.4	79
96	Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects. Cancer Research, 2005, 65, 9089-9098.	0.4	47
97	Antigen-Specific CD8+ T Lymphocytes Generated from a DNA Vaccine Control Tumors Through the Fas–FasL Pathway. Molecular Therapy, 2005, 12, 960-968.	3.7	16
98	Quantification of Relative Gene Dosage by Single-Base Extension and High-Performance Liquid Chromatography:Â Application to the SMN1/SMN2 Gene. Analytical Chemistry, 2005, 77, 6960-6968.	3.2	23
99	Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine, 2005, 23, 3864-3874.	1.7	28
100	Overexpression of Placenta Growth Factor Contributes to the Pathogenesis of Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 505-511.	2.5	76
101	Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-ÂB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis, 2004, 26, 45-52.	1.3	80
102	Overexpression of Her-2/ <i>neu</i> in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-κB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis. Journal of Biomedical Science, 2004, 11, 249-259.	2.6	4
103	Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 591-597.	1.3	10
104	Rapid detection of FGFR3 gene mutation in achondroplasia by DHPLC system-coupling heteroduplex and fluorescence-enhanced primer-extension analysis. Journal of Human Genetics, 2004, 49, 399-403.	1.1	11
105	Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. European Journal of Immunology, 2004, 34, 1892-1900.	1.6	14
106	In vivo wireless biodiagnosis system for long-term bioactivity monitoring network., 2004, 5394, 288.		0
107	Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 591-597.	1.3	5
108	Recent advances and problems in primary therapy for cervical cancer in Taiwan. Journal of the Formosan Medical Association, 2004, 103, 511-8.	0.8	12

#	Article	IF	Citations
109	Rapid detection of ?-globin gene (HBB) mutations coupling heteroduplex and primer-extension analysis by DHPLC. Human Mutation, 2003, 22, 326-336.	1.1	39
110	Simultaneous occurrence of hepatic focal nodular hyperplasia and uterine endometrial stromal nodule in a patient having treated breast infiltrating ductal carcinoma. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 585-586.	1.3	6
111	Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene, 2003, 22, 1517-1527.	2.6	463
112	Radical hysterectomy alone or combined with neoadjuvant chemotherapy in the treatment of early stage bulky cervical carcinoma. Journal of the Formosan Medical Association, 2002, 101, 195-202.	0.8	12
113	Cytosol Vascular Endothelial Growth Factor in Endometrial Carcinoma: Correlation with Disease-Free Survival. Gynecologic Oncology, 2001, 80, 207-212.	0.6	32
114	Interleukin-6 in Cervical Cancer: The Relationship with Vascular Endothelial Growth Factor. Gynecologic Oncology, 2001, 82, 49-56.	0.6	101
115	The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene, 2001, 20, 5799-5809.	2.6	149
116	Primary retroperitoneal teratoma. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 707-708.	1.3	11
117	Vascular Endothelial Growth Factor and Prognosis of Cervical Carcinoma. Obstetrics and Gynecology, 2000, 96, 721-726.	1.2	2
118	Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstetrics and Gynecology, 2000, 96, 615-621.	1.2	38
119	Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstetrics and Gynecology, 2000, 96, 721-726.	1.2	83
120	Vascular Endothelial Growth Factor in Cervical Carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	1.2	1
121	Pregnancy with Primary Tubal Placental Site Trophoblastic Tumor— A Case Report and Literature Review. Gynecologic Oncology, 1999, 73, 322-325.	0.6	47
122	Influence of Histologic Type and Age on Survival Rates for Invasive Cervical Carcinoma in Taiwan. Gynecologic Oncology, 1999, 73, 184-190.	0.6	97
123	Serum Vascular Endothelial Growth Factor in Epithelial Ovarian Neoplasms: Correlation with Patient Survival. Gynecologic Oncology, 1999, 74, 235-240.	0.6	89
124	Comparison between 'in vivo' and 'in vitro' methods for evaluating tumor angiogenesis using cervical carcinoma as a model. Angiogenesis, 1999, 3, 295-304.	3.7	10
125	Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma., 1999, 85, 651-657.		95
126	Vascular endothelial growth factor in cervical carcinoma. Obstetrics and Gynecology, 1999, 93, 761-765.	1.2	38

#	Article	IF	CITATIONS
127	Preoperative Ultrasound Study in Predicting Lymph Node Metastasis for Endometrial Cancer Patients. Gynecologic Oncology, 1998, 71, 424-427.	0.6	24
128	Clinical application of intratumoral blood flow study in patients with endometrial carcinoma. , $1998$ , $82$ , $1881$ - $1886$ .		29
129	Clinical application of intratumoral blood flow study in patients with endometrial carcinoma. Cancer, 1998, 82, 1881-1886.	2.0	2
130	Factors influencing tumor cell kinetics in cervical cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 504-508.	1.2	5
131	Coexistence of human cytomegalovirus and human papillomavirus type 16 correlates with lymph node metastasis in cervical cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 629-632.	1.2	18
132	Endometrial stromal sarcoma of twenty cases. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 551-555.	1.3	23
133	Successful treatment of a combined interstitial and intrauterine pregnancy after tubal embryo transfer (TET). Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 752-755.	1.3	4
134	Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color doppler ultrasound. Cancer, 1995, 75, 2518-2522.	2.0	43
135	Systemic Lymphadenopathy as the Primary Symptom of Serous Surface Papillary Carcinoma of the Ovary. Gynecologic Oncology, 1995, 58, 251-254.	0.6	9
136	Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. Carcinogenesis, 1994, 15, 2221-2223.	1.3	18
137	Vascular patterns of gestational trophoblastic tumors by color doppler ultrasound. Cancer, 1994, 74, 2361-2365.	2.0	44
138	The genotypes and prognostic significance of human papillomaviruses in cervical cancer. International Journal of Cancer, 1994, 57, 181-184.	2.3	47
139	Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer. Journal of Cancer Research and Clinical Oncology, 1994, 120, 678-682.	1.2	5
140	Cell kinetics and radiosensitivity of cervical squamous cell carcinoma. Cancer Letters, 1994, 82, 135-140.	3.2	3
141	Correlation of Uterine Hemodynamics With Chemotherapy Response in Gestational Trophoblastic Tumors. Obstetrics and Gynecology, 1994, 83, 1021-1025.	1.2	20
142	The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin. Gynecologic Oncology, 1992, 47, 28-33.	0.6	10